TALLC to introduce TA-A001, our proprietary CB2R agonist, and the enabling effects of SmartCelle ocular delivery technology at the Ophthalmology Innovation Summit: Drug Delivery Showcase.
See our updated presentation describing TA-A001 for neovascular disease, wound healing and new ocular bio-distribution data
https://informaconnect.com/chinabio-partnering/
